|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
CA2513113A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
|
WO2011123830A2
(en)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
EP2552967A4
(en)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
|
MX340556B
(es)
*
|
2010-08-24 |
2016-07-14 |
Roche Glycart Ag |
Anticuerpos biespecificos activables.
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
SG10201608307WA
(en)
|
2012-04-20 |
2016-11-29 |
Emergent Product Dev Seattle |
Cd3 binding polypeptides
|
|
CN104540518A
(zh)
*
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
JP6092649B2
(ja)
|
2013-02-15 |
2017-03-08 |
キヤノン株式会社 |
演算装置、アレイ型演算装置およびその制御方法、情報処理システム
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
CN110627907B
(zh)
|
2013-11-04 |
2024-03-29 |
艾科诺斯科技股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
BR112016015140A2
(pt)
|
2013-12-30 |
2018-01-23 |
Epimab Biotherapeutics Inc. |
imunoglobulina com fabs in-tandem e usos das mesmas
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
CN105820248A
(zh)
|
2015-01-07 |
2016-08-03 |
上海张江生物技术有限公司 |
一种新型抗egfr单克隆抗体的制备方法及应用
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
WO2017008169A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
CN114423499A
(zh)
*
|
2019-06-06 |
2022-04-29 |
佳努克斯治疗公司 |
与肿瘤激活的t细胞衔接子相关的组合物和方法
|
|
US20230121775A1
(en)
|
2019-06-26 |
2023-04-20 |
Amunix Pharmaceuticals, Inc. |
Cd3 antigen binding fragments and compositions comprising same
|
|
CA3143522A1
(en)
|
2019-06-26 |
2020-12-30 |
Amunix Pharmaceuticals, Inc. |
Egfr antigen binding fragments and compositions comprising same
|
|
KR20210043475A
(ko)
|
2019-10-10 |
2021-04-21 |
주식회사 와이바이오로직스 |
다중 특이적 융합 단백질 및 이의 용도
|
|
JP2024518539A
(ja)
|
2020-04-04 |
2024-05-01 |
ジャナックス セラピューティクス，インク． |
抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
|
|
WO2022035866A1
(en)
|
2020-08-11 |
2022-02-17 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
WO2022094299A2
(en)
|
2020-10-30 |
2022-05-05 |
Janux Therapeutics, Inc. |
Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
|
|
EP4259177A4
(en)
|
2020-12-08 |
2024-11-06 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
EP4337794A4
(en)
|
2021-05-11 |
2025-07-02 |
Janux Therapeutics Inc |
ANTIBODIES TARGETING EGFR AND CD3 AND THEIR USES
|
|
WO2024102723A2
(en)
|
2022-11-10 |
2024-05-16 |
Janux Therapeutics, Inc. |
Antibodies targeting egfr and cd3 and uses thereof
|
|
EP4615879A2
(en)
|
2022-11-11 |
2025-09-17 |
Janux Therapeutics, Inc. |
Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
|